HLX70, a recombinant humanized anti-S protein monoclonal antibody intended for intravenous infusion, was under investigation in clinical trials NCT05429385 and NCT04561076 to evaluate its safety and pharmacokinetics in healthy adult... The condition targeted by HLX70 in this study is COVID-19.
- Mechanism
- Curator reviewed
HLX70 is a genetically engineered anti-spike protein-1 fully-humanized monoclonal antibody and a typical IgG1 Kappa immunoglobulin. It targets the receptor-binding domain (RBD) of the S1 subunit of the spike protein of SARS-CoV-2, competitively binding at this domain with a higher affinity to block the human angiotensin II converting enzyme 2 with viral RBD, which protects the cells from viral entry and infection.
- Code names
- HLX70
Resolves to
What you can answer from here — as of July 08, 2026
Which drugs share a target with HLX70, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account